contrast induced nephropathy
Conditions
Interventions
metformin group:treatment with metformin (Glucophage, Bristol-Myers Squibb brand), 850mg 2 times/day, from 2 days before and to 3 days after contrast medium administration
control group:the control group did not receive any metformin
Sponsors
Department of Cardiology, Zhongda Hospital of Southeast University Medical School
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) volunteered to participate in this trial and signed informed consent; (2) Aged 18 to 85 Years; (3) Planned cardiac catheterization procedures; (4) CKD stages 2, eGFR = 60ml/min per 1.73m2; (5) T2DM (dignosed <5 years).
Exclusion criteria
Exclusion criteria: (1) a history of received metformin (14 days); (2) Hypersensitivity to iodine-containing compounds; (3) eGFR<60ml/min per 1.73m2); (4) acute ST-segment elevation myocardial infarction (STEMI); (5) NYHA class IV or hemodynamic instability; Administration of ACEI/ARB within 14 days before randomization; (6) Take CT, MRI and other examinations with contrast agents during the two weeks before study; take radiographic examination of other contrast agents during the study period; (7) blood pressure <120/80mmHg; (8) Hepatic dysfunction (ALT 3 times greater than upper normal limit); (9) Thyreoid insufficiency; (10) Malignant tumors, inflammatory diseases, autoimmune diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome Measures:The incedence of CIN; | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome Measures: The composite of hospitalization for aggravated renal function, acute renal failure, dialysis or hemofiltration, aggravated at least 1 class of heart function, acute left ventricular failure or death from all causes occurring within 30 days after contrast.; | — |
Countries
China
Contacts
Public ContactChengchun Tang
Department of Cardiology, Zhongda Hospital of Southeast University Medical School
Outcome results
None listed